Prior Auth Required

02141 - 2 Xenpozyme prescribing information, Genzyme Corporation, Cambridge, MA . 12/23 9/24

This procedure appears on the selected insurer prior authorization source.

Check another codeExplore policy data
Prior authorizationPrior Auth Required
Procedure / Service2 Xenpozyme prescribing information, Genzyme Corporation, Cambridge, MA . 12/23 9/24
Procedure / Service Description

Updated Accessed - 1 National Organization for Rare Disorders (NORD) - Acid Sphingomyelinase Deficiency. Published 2019. 9/22 9/24 Available at: https://rarediseases.org/rare-diseases/acid-sphingomyelinase-deficiency/ 2 Xenpozyme prescribing information, Genzyme Corporation, Cambridge, MA 02141. 12/23 9/24 3 Wasserstein MP, et al. Olipudase alfa for treatment of acid sphingomyelinase deficiency (ASMD): safety and 2018 11/22 efficacy in adults treated for 30 months. J Inherit Metab Dis. 2018 Sep; 41(5):829-838.

Likely documents
  • Confirm benefit details
  • Submit clinical notes if requested by the plan
Next actions
  • Confirm the current plan policy before submission.
  • Use the insurer authorization workflow for this listed code.